During the COVID years, I had more conversations than I can count that started with some version of: “Doc… what do you think about this mRNA stuff?” Back then, “mRNA vaccine” could instantly shift the emotional temperature in the room—curiosity for some, skepticism for others, and sometimes real fear or anger.
What’s striking, looking back, is that while mRNA technology was being debated in the public square, it was also quietly being used in oncology research in a very different way: as a personalized tool to teach the immune system what a specific patient’s cancer looks like.
This week brought a reminder of that progress. On January 20, 2026, Merck and Moderna announced a pre-planned 5-year follow-up from the phase 2b KEYNOTE-942 / mRNA-4157-P201 study in resected high-risk stage III/IV melanoma—and the benefit they reported appears to be holding up over time.
First: what kind of “cancer vaccine” is this?
This is not a prevention vaccine like measles or HPV. It’s an individualized neoantigen therapy—a personalized vaccine built from the genetic “fingerprint” of a patient’s tumor.
Here’s the simple version:
- Your tumor has mutations.
- Some mutations create new “flags” (neoantigens) that the immune system could recognize as abnormal.
- This platform selects a set of those neoantigens (up to 34) and encodes them into an mRNA sequence.
- After injection, the body uses those instructions to briefly make pieces of those targets, training T cells to recognize the tumor’s unique flags.
And then you pair that training with something we already know works in melanoma: PD-1 blockade, which helps reinvigorate anti-tumor T cells—here, pembrolizumab.
The study in plain language
KEYNOTE-942 enrolled 157 patients with high-risk stage III/IV melanoma after complete surgical resection, and randomized them 2:1 to:
- mRNA-4157 (V940 / intismeran autogene) + pembrolizumab, or
- pembrolizumab alone (standard adjuvant immunotherapy).
This “after surgery” (adjuvant) setting matters. Even with excellent surgery and modern therapy, recurrence risk remains substantial for many stage III/IV patients—one reason adjuvant anti–PD-1 therapy became a standard option.
What’s new in the 5-year update
In the company press release, the median ~5-year follow-up analysis reported:
- 49% relative reduction in the risk of recurrence or death with the combination vs pembrolizumab alone
- HR 0.510 (95% CI 0.294–0.887), nominal one-sided p=0.0075
A few important “editor notes” for how to interpret this responsibly:
- This 5-year update is coming via press release—meaning we don’t yet have the full dataset presentation (curves, censoring details, subgroups, etc.) in a peer-reviewed format.
- Merck/Moderna state additional endpoint and follow-up analyses will be presented at an upcoming meeting.
Still, the headline is meaningful: the signal appears durable—and in melanoma, durability is the point.
What we knew already (and why durability matters)
This wasn’t the first time we saw this combination look promising.
- The randomized phase 2b trial results were published in The Lancet (2024), showing improved recurrence-free survival and distant metastasis–free survival with the combination vs pembrolizumab alone.
- A 3-year update was presented at ASCO 2024 (JCO supplement abstract), continuing to show a clinically meaningful separation in outcomes and describing a safety profile consistent with prior reporting.
Now the story is: the advantage hasn’t “faded out” with longer follow-up—at least based on what has been publicly reported so far.
What about side effects?
When I think back to patients I treated on similar protocols, the word that keeps coming up is: tolerable.
In earlier public reports, the most common symptoms in the combination arm looked like what many people recognize from immune activation and vaccination:
- fatigue, injection-site pain, chills, fever, headache
…and importantly, rates of grade ≥3 adverse events were similar between groups in the 3-year update reporting.
As always, “tolerable” doesn’t mean “trivial,” and immune therapy can have serious toxicities. But the overall safety narrative here has been reassuring relative to what many of us fear when we add something new on top of a checkpoint inhibitor.
Why this matters in the real world
Adjuvant anti–PD-1 therapy is already a cornerstone in melanoma care in multiple resected stages, supported by major guidelines and regulatory decisions.
But even with strong standards of care, too many patients recur. The whole point of innovation in the adjuvant setting is to push relapse rates lower—without paying an unacceptable price in toxicity.
If these results hold up in phase 3, this approach could represent something we’ve wanted for a long time:
a truly personalized “immune education” strategy that adds on top of checkpoint blockade.
The next milestone: phase 3 and beyond
The next big question is whether a larger phase 3 trial confirms the benefit.
Merck and Moderna report the phase 3 adjuvant melanoma study INTerpath-001 (NCT05933577) is fully enrolled, with additional trials underway across other tumor types.
That’s the moment the field is waiting for—not because phase 2b data aren’t encouraging, but because phase 3 is where we learn how reproducible and practice-changing a signal really is.
Back to that clinic conversation: “mRNA” as a tool, not a slogan
One reason I wanted to write this now is that I still meet people who hear “mRNA” and think politics before they think biology.
In medicine, mRNA is not a belief system. It’s a delivery method—a set of instructions. In infectious disease, those instructions can help the immune system prepare for a virus. In cancer, those instructions can help the immune system recognize a tumor’s unique fingerprint.
Different villains. Same elegant toolbox.
And for patients sitting in front of us after a melanoma surgery—worried, hopeful, exhausted—that distinction matters. Because if we can safely reduce the chance the cancer returns, that’s not an abstract scientific victory. That’s more birthdays, more ordinary days, more future.
Dr. Sajeve Thomas is a distinguished medical professional and a compassionate guide in the field of oncology. With over a decade of dedicated experience as a board-certified medical oncologist/internal medicine specialist, Dr. Thomas has become a trusted expert in the treatment of melanoma, sarcoma, and gastrointestinal conditions. He brings a wealth of expertise to the complex and challenging world of oncology.
Disclosures:
Dr. Thomas serves as a speaker for BMS, Merck, Ipsen, Natera, Immunocore, Pfizer, Sun Pharma, SpringWorks. He also receives industry grants in support of numerous clinical trials.